source
- Eli Lilly to acquire Calytrix Bio for up to $1.5B, targeting rare blood cancersEli Lilly announced it will acquire Calytrix Bio, a Massachusetts biotech, in a deal valued at up to $1.5 billion. Calytrix focuses on precision therapies for myeloproliferative neoplasms, includi…
- Seawolf Therapeutics raises $100M and secures up to $1.2B partnership with Sanofi for redosable DNA medicinesSeawolf Therapeutics announced a $100 million Series A financing backed by investors including Novartis Venture Fund, Eli Lilly, CRISPR Therapeutics and others. The company also disclosed a multi‑…